Further investigations regarding PSCA polymorphisms and their functions are required to provide pathophysiological findings and establish reliable biomarkers, finally leading to the development of new therapeutic GMA drugs to reduce gastric cancer risk. This evidence concerns the gene PSCA and gastric cancer.